Search results
Author(s):
Braghadheeswar Thyagarajan
,
Ankur Kalra
,
Alefiyah Rajabali
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common arrhythmia in patients with hypertrophic cardiomyopathy (HCM), with a reported prevalence of AF in HCM of about 25 %.1 Patients with AF in HCM tend to be more symptomatic and have an increased stroke risk compared with patients without HCM.2 While the occurrence and treatment of (symptomatic) AF in HCM have been extensively studied, there is little data…
View more
Author(s):
Ankur Kalra
,
Added:
8 months ago
Join Dr Ankur Kalra in this episode of our mini-series, "Conversations about Hypertrophic Cardiomyopathy", as he engages in an in-depth discussion with Dr Carolyn Yung Ho. Together, they explore the journey from symptoms to diagnosis and management options for hypertrophic cardiomyopathy (HCM).
Click here to listen to the podcast version.
This content is intended for US-based physicians.
…
View more
Author(s):
Milind Y Desai
Added:
1 year ago
In this short summary interview, Dr Milind Y Desai (Cleveland Clinic, US) shares the findings from the VALOR-HCM trial (MyoKardia) (NCT04349072).
This randomised, multicentre study was designed to assess the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy.
Discussion…
View more
Navigating HCM Management Paradigms with Dr Masri
Author(s):
Ankur Kalra
,
Ahmad Masri
Added:
8 months ago
Podcast Episode
Author(s):
Ahmad Masri
Added:
10 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that…
View more
Author(s):
Rachel Lampert
,
Michael Ackerman
,
Sharlene Day
Added:
1 year ago
ACC.23/WCC—We are joined onsite by principal investigator Dr Rachel Lampert (Yale School of Medicine, US), Dr Sharlene Day (Penn Medicine, US) and Dr Michael Ackerman (Mayo Clinic, US) to discuss the late-breaking findings from the LIVE-HCM Study. In this trial, investigators aimed to determine the effects of lifestyle and exercise on the well-being of patients with hypertrophic cardiomyopathy …
View more
Martin S Maron
Author
Ethan J Rowin
Author
Author(s):
Florian Rader
Added:
1 year ago
This interview with Dr Florian Rader (Cedars-Sinai Medical Center, Los Angeles, CA, US) focuses on the interim results of the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655).
This study is the largest and longest report of mavacamten that investigated 310 patients with symptomatic obstructive HCM for over 252 weeks. Originally presented at the ACC.22, these results show that treatment…
View more
Author(s):
Sara Saberi
Added:
1 year ago
HFSA 2022 — Dr Sara Saberi (University of Michigan School of Medicine, US) joins us to talk about the findings of the REDWOOD-HCM OLE. This 5-year extension study showed improvement in KCCQ scores in patients with obstructive hypertrophic cardiomyopathy (HCM) treated with aficamten (Cytokinetics), a novel cardiac myosin inhibitor (NCT04219826).
Questions
1. What are some of the unmet needs in…
View more